Neurocrine Biosciences, Inc.
US ˙ NasdaqGS ˙ US64125C1099

SecurityNBIX / Neurocrine Biosciences, Inc.
InstitutionCinctive Capital Management LP
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Cinctive Capital Management LP closes position in NBIX / Neurocrine Biosciences, Inc.

On November 14, 2025 - Cinctive Capital Management LP filed a 13F-HR form disclosing ownership of 0 shares of Neurocrine Biosciences, Inc. (US:NBIX) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 4,766 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -4,766 -100.00 0 -100.00
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,766 4,766 599 0.0317
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -16,366 -100.00 0 -100.00
2025-02-12 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,366 16,366 2,234 0.1137
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -9,983 -100.00 0 -100.00
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,983 9,983 1,377 0.0640
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -67,825 -100.00 0 -100.00
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 67,825 -35,948 -34.64 5,777 -41.96 0.2541
2021-11-15 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 103,773 26,734 34.70 9,953 32.76 0.4871
2021-08-16 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 77,039 28,248 57.90 7,497 58.00 0.3502
2021-05-17 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 48,791 48,791 4,745 0.2903
2020-11-16 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -33,393 -100.00 0 -100.00
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 33,393 -1,289 -3.72 4,074 35.71 0.4674
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 34,682 34,682 3,002 0.6678
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.